Critic at Large

» disease/medicine, science publishing and culture

Most Recent

image: Misconduct Around the Globe

Misconduct Around the Globe

By Richard Smith and Tracey Koehlmoos | June 1, 2013

Research misconduct is not limited to the developed world, but few countries anywhere are responding adequately.

3 Comments

image: Cancer Clinical Trials of Tomorrow

Cancer Clinical Trials of Tomorrow

By Tomasz M. Beer | April 1, 2013

Advances in genomics and cancer biology will alter the design of human cancer studies.

0 Comments

image: Genomics-Informed Pathology

Genomics-Informed Pathology

By Dennis P. Wall and Peter J. Tonellato | January 1, 2013

Twenty-first century lab reports will include test results read by a new breed of pathologist.

1 Comment

image: Military Mind Wars

Military Mind Wars

By Jonathan D. Moreno | November 1, 2012

How neuroscience research can inform military counterintelligence tactics, and the moral responsibilities that accompany such research

5 Comments

image: Medicines for the World

Medicines for the World

By Suerie Moon and Ellen ’t Hoen | October 1, 2012

A global R&D treaty could boost innovation and improve the health of the world’s poor—and rich.

0 Comments

image: Bring On the Transparency Index

Bring On the Transparency Index

By Adam Marcus and Ivan Oransky | August 1, 2012

Grading journals on how well they share information with readers will help deliver accountability to an industry that often lacks it.

6 Comments

image: Predatory Publishing

Predatory Publishing

By Jeffrey Beall | August 1, 2012

Overzealous open-access advocates are creating an exploitative environment, threatening the credibility of scholarly publishing.

32 Comments

image: All’s Not Fair in Science and Publishing

All’s Not Fair in Science and Publishing

By Frederick Southwick | July 1, 2012

False credit for scientific discoveries threatens the success and pace of research.

72 Comments

image: Polypharmacy

Polypharmacy

By Catherine Ulbricht | July 1, 2012

Dietary supplements can have serious side effects when mixed with prescription drugs, but not all herb-drug interactions are bad.

14 Comments

image: Regulations for Biosimilars

Regulations for Biosimilars

By Lisa A. Haile and Kimberly K. Egan | June 1, 2012

As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?

2 Comments

Popular Now

  1. Sci-Hub Loses Domains and Access to Some Web Services
  2. Nobel Prize–Winning Biologist Dies
  3. CDC: Flu Vaccine 36 Percent Effective So Far
  4. Academics Protest China’s Censorship Requests
AAAS